The foregoing findings suggested that a common mechanism to explain the effects of structurally diverse Myc inhibitors on cancer cell survival and/or differentiation might be their ability to deplete cellular ATP pools as a consequence of their dual effects on Myc protein abundance and function and, ultimately, on glycolysis and Oxphos. This evidence concerns the gene MYC and cancer.